Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ACVBP vs DA-EPOCH-R in Newly Diagnosed Non-GCB DLBCL
NCT03018626Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, pegylated liposomal doxorubicin, cyclophosphamide, vindesine, bleomycin and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Progression-free survival at 3 years. Status: unknown.
02
Drugs
rituximabpegylated liposomal doxorubicincyclophosphamidevindesinebleomycin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03018626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018626.